

Technical University of Denmark



Determinants of the VP1/2A junction cleavage by the 3C protease in foot-and-mouth disease virus infected cells

Kristensen, Thea; Normann, Preben; Gullberg, Maria; Fahnøe, Ulrik; Polacek, Charlotta; Rasmussen, Thomas Bruun; Belsham, Graham

Published in:
Journal of General Virology

Link to article, DOI:
[10.1099/jgv.0.000664](https://doi.org/10.1099/jgv.0.000664)

Publication date:
2017

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Kristensen, T., Normann, P., Gullberg, M., Fahnøe, U., Polacek, C., Rasmussen, T. B., & Belsham, G. (2017). Determinants of the VP1/2A junction cleavage by the 3C protease in foot-and-mouth disease virus infected cells. *Journal of General Virology*, 98, 385-395. DOI: 10.1099/jgv.0.000664

DTU Library

Technical Information Center of Denmark

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Journal of General Virology

Determinants of the VP1/2A junction cleavage by the 3C protease in foot-and-mouth disease virus infected cells

--Manuscript Draft--

Manuscript Number:	JGV-D-16-00608R1
Full Title:	Determinants of the VP1/2A junction cleavage by the 3C protease in foot-and-mouth disease virus infected cells
Article Type:	Standard
Section/Category:	Animal - Positive-strand RNA Viruses
Corresponding Author:	Graham J. Belsham Technical University of Denmark (DTU) Kalvehave, DENMARK
First Author:	Thea Kristensen
Order of Authors:	Thea Kristensen Preben Normann Maria Gullberg Ulrik Fahnøe Charlotta Polacek Thomas Bruun Rasmussen Graham J. Belsham
Abstract:	<p>The foot-and-mouth disease virus (FMDV) capsid precursor, P1-2A, is cleaved by FMDV 3C protease to yield VP0, VP3, VP1 and 2A. Cleavage of the VP1/2A junction is the slowest. Serotype O FMDVs with uncleaved VP1-2A (having a K210E substitution in VP1; at position P2 in cleavage site) have been described previously and acquired a second site substitution (VP1 E83K) during virus rescue. Furthermore, introduction of the VP1 E83K substitution alone generated a second site change at the VP1/2A junction (2A L2P, position P2' in cleavage site). These virus adaptations have now been analysed using Next Generation Sequencing to determine sub-consensus level changes in the virus; this revealed other variants within the E83K mutant virus population that changed residue VP1 K210. The construction of serotype A viruses with a blocked VP1/2A cleavage site (containing K210E) has now been achieved. A collection of alternative amino acid substitutions were made at this site and the properties of the mutant viruses determined. Only the presence of a positively charged residue at position P2 in the cleavage site permitted efficient cleavage of the VP1/2A junction, consistent with analyses of diverse FMDV genome sequences. Interestingly, in contrast to the serotype O virus results, no second site mutations occurred within the VP1 coding region of serotype A viruses with the blocked VP1/2A cleavage site. However, some of these viruses acquired changes in the 2C protein that is involved in enterovirus morphogenesis. These results have implications for the testing of potential antiviral agents targeting the FMDV 3C protease.</p>

1 **Determinants of the VP1/2A junction cleavage by the 3C protease in foot-and-mouth disease**
2 **virus infected cells**

3

4 Thea Kristensen¹, Preben Normann¹, Maria Gullberg¹, Ulrik Fahnøe^{1,2}, Charlotta Polacek¹, Thomas
5 Bruun Rasmussen¹ and Graham J. Belsham^{1#}.

6

7 ¹National Veterinary Institute, Technical University of Denmark, Lindholm, DK-4771 Kalvehave,
8 Denmark.

9 ²Current address: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and
10 Clinical Research Centre, Hvidovre Hospital and Department of International Health, Immunology and
11 Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

12

13 #Corresponding author.

14 Mailing address: National Veterinary Institute, Technical University of Denmark, Lindholm, DK-
15 4771 Kalvehave, Denmark.

16 Phone: +45 3588 7985. Fax: +45 3588 7901. E-mail: grbe@vet.dtu.dk

17

18 Running title: VP1/2A cleavage within FMDV-infected cells.

19

20 Keywords: picornavirus; polyprotein processing; cleavage specificity; virus capsid assembly;
21 proteolysis

22

23 Abstract word count: 250; Text word count: 4900 (excl. Abstract, references, Figure legends)

24

25 Figures 5; Tables 3; Supplementary Table: S1

26 **Abstract**

27 The foot-and-mouth disease virus (FMDV) capsid precursor, P1-2A, is cleaved by FMDV 3C
28 protease to yield VP0, VP3, VP1 and 2A. Cleavage of the VP1/2A junction is the slowest. Serotype
29 O FMDVs with uncleaved VP1-2A (having a K210E substitution in VP1; at position P2 in cleavage
30 site) have been described previously and acquired a second site substitution (VP1 E83K) during virus
31 rescue. Furthermore, introduction of the VP1 E83K substitution alone generated a second site change
32 at the VP1/2A junction (2A L2P, position P2' in cleavage site). These virus adaptations have now
33 been analysed using Next Generation Sequencing to determine sub-consensus level changes in the
34 virus; this revealed other variants within the E83K mutant virus population that changed residue VP1
35 K210. The construction of serotype A viruses with a blocked VP1/2A cleavage site (containing
36 K210E) has now been achieved. A collection of alternative amino acid substitutions were made at
37 this site and the properties of the mutant viruses determined. Only the presence of a positively charged
38 residue at position P2 in the cleavage site permitted efficient cleavage of the VP1/2A junction,
39 consistent with analyses of diverse FMDV genome sequences. Interestingly, in contrast to the
40 serotype O virus results, no second site mutations occurred within the VP1 coding region of serotype
41 A viruses with the blocked VP1/2A cleavage site. However, some of these viruses acquired changes
42 in the 2C protein that is involved in enterovirus morphogenesis. These results have implications for
43 the testing of potential antiviral agents targeting the FMDV 3C protease.

44

45 **Introduction**

46 Foot-and-mouth disease virus (FMDV) is the prototypic member of the *Aphthovirus* genus within the
47 family *Picornaviridae* and seven different serotypes (O, A, C, SAT 1-3 and Asia-1) have been
48 identified. All FMDVs have a positive sense RNA genome (ca. 8400 nt) that includes a single large
49 open reading frame (ca. 7000 nt) encoding a polyprotein (Belsham, 2005). The full-length polyprotein

50 is never observed since during, and after, synthesis it is processed, mainly by virus-encoded proteases,
51 to generate 15 distinct mature products plus multiple precursors. The FMDV polyprotein includes
52 two *trans*-acting proteases; these are the Leader (L) protease and the 3C protease (3C^{pro}). The L
53 protease is only responsible for one cleavage within the polyprotein that occurs at its own C-terminus
54 (i.e. the L/P1-2A junction, Strebel & Beck, 1986; Medina *et al.*, 1993). However, this protease also
55 induces cleavage of the translation initiation factor eIF4G, this results in the inhibition of host cell,
56 cap-dependent, protein synthesis (reviewed in Belsham, 2005). The 3C^{pro} cleaves all the other
57 junctions within the FMDV polyprotein except for the VP4/VP2 junction and the 2A/2B junction.
58 Cleavage of VP0 to VP4 and VP2 occurs on encapsidation of the viral RNA and also within
59 assembled empty capsid particles (Curry *et al.*, 1995; Gullberg *et al.*, 2013a; Gullberg *et al.*, 2013b).
60 Separation of the 2A peptide from the 2B protein is dependent on the 2A coding sequence. However,
61 this region only encodes 18 amino acids (without any protease motifs) but its presence results in a
62 break in the polyprotein during its synthesis; this is described as “ribosomal skipping” (Donnelly *et*
63 *al.*, 2001) or “StopGo” (Atkins *et al.*, 2007).

64 The FMDV capsid protein precursor, P1-2A (Fig. 1), is processed by the 3C^{pro} to VP0, VP3, VP1 and
65 2A. The scission of the VP1-2A junction is the slowest of these cleavages within cell-free translation
66 systems (Ryan *et al.*, 1989) and within mammalian cells (Gullberg *et al.*, 2013a; Gullberg *et al.*,
67 2013b) since the uncleaved VP1-2A can still be detected when all other junctions are fully cleaved
68 (e.g. when P1-2A is expressed with a low-level of 3C^{pro}). However, in peptide cleavage assays, using
69 short synthetic substrates, it has been found that the peptide corresponding to the VP1/2A cleavage
70 site was the most rapidly processed (Birtley *et al.*, 2005).

71 The FMDV 3C^{pro} cleaves a variety of different junction sequences (the amino acid residues at the
72 cleavage junctions are indicated as: P4P3P2P1/P1'P2'P3'P4'). The cleavage sites recognized by the
73 FMDV 3C^{pro} have either glutamine (Gln, Q) or glutamate (Glu, E) at the P1 position (Curry *et al.*,

74 2007). The consensus sequence (in single letter code) for the VP1/2A junction in serotype O and A
75 FMDVs is PxKQ/xLNF. The Q residue at the P1 position together with the P4-Pro (P), P2-Lys (K)
76 and P4'-Phe (F) residues, represent key determinants of 3C^{pro} specificity at this site (Birtley *et al.*,
77 2005; Curry *et al.*, 2007; Zunszain *et al.*, 2010). Analysis of aligned FMDV 3C^{pro} cleavage sites from
78 over 100 strains of the virus (including representatives of all serotypes) revealed that sites with P1-Q
79 have a strong selectivity for P2-K, indicating that recognition of the P1 residue by 3C^{pro} is influenced
80 by the P2 residue (Curry *et al.*, 2007). Recently, we have shown that changing the P2-K residue to E
81 at the VP1/2A junction (i.e. K210E in VP1), in a serotype O virus, greatly inhibited cleavage at this
82 junction and resulted in the formation of infectious virus particles containing the uncleaved VP1-2A
83 (Gullberg *et al.*, 2013b). The “self-tagged” viruses containing this modification (K210E) also
84 acquired, during the virus rescue procedure, a second amino acid substitution within VP1 (E83K).
85 Interestingly, introduction of this E83K substitution alone into the virus, generated a second site
86 mutant (L2P, in the 2A sequence; this is position P2' in the VP1/2A junction) that also blocked
87 cleavage (Gullberg *et al.*, 2014). We have now expanded this analysis to identify the determinants of
88 cleavage at the VP1/2A junction within the context of infectious serotype O and A FMD viruses using
89 a variety of different approaches. Within the serotype A FMDVs, no second site changes in VP1 were
90 observed in viruses where the VP1/2A cleavage was inhibited, but some evidence for changes in 2C
91 was obtained. For certain picornaviruses, within the enterovirus genus, interactions between the virus
92 capsid proteins and the 2C non-structural protein have been implicated in the process of virus
93 morphogenesis (Liu *et al.*, 2010; Wang *et al.*, 2012; Wang *et al.*, 2014).

94

95 **Results**

96 *Modification of the VP1/2A cleavage site in a serotype A FMDV.*

97 In order to determine whether the key elements of the results obtained with the serotype O FMDV
98 sequences (Gullberg *et al.*, 2014) also applied to serotype A FMDV, the effect of modifying the

99 VP1/2A cleavage site within a serotype A FMDV was examined. The VP1/2A cleavage site sequence
100 in the A22 strain of FMDV (APAKQ/LLNFD) differs at just 1 out of the 10 residues flanking the
101 junction from the serotype O (strain O1 Manisa, abbreviated throughout as O1M) sequence
102 (APVKQ/LLNFD) analysed previously (Gullberg *et al.*, 2013b; Gullberg *et al.*, 2014) (see Fig. 1).
103 The K210E substitution (at the P2 position) was introduced into a full-length FMDV cDNA, based
104 on the backbone of a chimeric O1 Kaufbeuren (O1K) virus containing the coding sequence for the
105 VP2-VP3-VP1-2A region of the A22 capsid protein precursor (Fig.1). Virus was successfully rescued
106 from this chimeric wt O1K/A22 plasmid and also from the O1K/A22 VP1 K210E mutant (this had
107 changed the codon encoding VP1 residue 210 from AAA to GAA). However, when the capsid protein
108 coding sequences within the rescued virus were determined, it was found that the K210E substitution
109 in VP1 had reverted in the virus by passage 2 (Psg 2) to the wt sequence (this only requires a single
110 nt change) (see Fig. 1).

111 Two further modifications were, therefore, introduced into the serotype A viruses, the 2A L2P
112 modification was made in isolation (using 3 nt changes, TTG to CCA) and a double mutant containing
113 both the K210E substitution (the single nt change) and the 2A L2P substitution. Viruses were rescued
114 successfully from both of these mutant plasmids. Consensus sequencing indicated that the expected
115 mutations were still present within these rescued viruses and that no other mutations were detected
116 within the VP2-2A coding region (see Fig. 1).

117 Analysis of the FMDV capsid proteins within cells infected with the wt and mutant O1K/A22 viruses,
118 as determined by immunoblotting using anti-VP2 and anti-2A antibodies, is shown in Fig. 2. As
119 expected, the production of VP0 and VP2 was very similar in each of the infected cell extracts (Fig.
120 2(a), lanes 2-7). However, the presence of the uncleaved VP1-2A was only observed with the mutant
121 viruses, either containing the 2A L2P substitution alone (Fig. 2(b), lanes 4 and 5) or with the double
122 mutant (VP1 K210E and 2A L2P) (Fig. 2(b), lanes 6 and 7).

123 These results were confirmed using immunofluorescence (IF) studies (Fig. 3). Consistent with the
124 immunoblotting data, the presence of FMDV 2A (still attached to VP1) was detected in cells infected
125 with the O1K/A22 2A L2P mutant virus (Fig. 3(g)) and with the double mutant (O1K/A22 VP1
126 K210E and 2A L2P) virus (Fig. 3(h)). In contrast, no signal for the 2A peptide was observed in cells
127 infected with the wt O1K/A22 virus (Fig. 3(f)) or in uninfected cells (Fig. 3(e)). The presence of the
128 FMDV capsid proteins could be detected in cells infected with each of the viruses (Fig. 3(b-d)) but
129 not in uninfected cells (Fig. 3(a)). These results are consistent with those obtained using the serotype
130 O FMDVs previously (Gullberg *et al.*, 2014). It seems that the free 2A peptide is not efficiently
131 detected within cells using the IF approach; it is assumed that either it breaks down very quickly or
132 the conditions of the IF assay are not suitable for detection of this short peptide.

133

134 *Use of NGS to determine sequence diversity within rescued FMDVs.*

135 As described previously (Gullberg *et al.*, 2013b; Gullberg *et al.*, 2014), consensus sequencing of the
136 capsid coding region (P1-2A) of the serotype O FMDVs rescued from the K210E and E83K mutant
137 forms of the O1K/O1M cDNAs identified the presence of additional amino acid substitutions in the
138 rescued viruses. We wished to analyse these adaptations in more detail, in particular to examine the
139 appearance of sub-consensus level changes throughout the near complete genome sequence including
140 the complete polyprotein coding region. To achieve this, RNA was extracted from the rescued
141 O1K/O1M VP1 E83K and O1K/O1M VP1 K210E viruses (as described by Gullberg *et al.*, 2013b;
142 Gullberg *et al.*, 2014) at Psg 2 and/or Psg 3. Two separate, but overlapping, cDNA fragments
143 including the near complete genome (ca. 8kb, downstream of the poly(C) tract) were produced by
144 RT-PCR, mixed and then sequenced using NGS at a coverage of about 5,000 reads per nt (except
145 near the extreme 5'- and 3'-termini).

146 This analysis showed that the rescued virus O1K/O1M VP1 E83K retained the expected substitution
147 (encoding E83K) in 100% of the progeny at Psg 2 but there was some heterogeneity in the sequence
148 near the VP1/2A junction (see Table 1). As described earlier, the consensus sequencing indicated that
149 a substitution (L2P) within the 2A sequence occurred within this rescued virus (Gullberg *et al.*, 2014).
150 The analysis by NGS (see Table 1) demonstrated that at Psg 2 some 83% of the reads corresponded
151 to this L2P substitution in 2A while two other variants were also present (albeit at relatively low
152 levels, 4% and 9%) which each encoded the K210N substitution in VP1 (c.f. the K210E change
153 described previously in O1M, (Gullberg *et al.*, 2014)). No other coding changes were present
154 anywhere in the genome at an abundance of more than 3%.

155 Consensus sequence analysis of the rescued O1K/O1M VP1 K210E virus has shown previously the
156 generation of the E83K substitution (Gullberg *et al.*, 2013b). Using NGS, it was found that the E83K
157 substitution in VP1 was encoded in 78% of the reads generated at Psg 2 and in 99% of the reads at
158 Psg 3 (Table 1), consistent with the earlier consensus sequencing (Gullberg *et al.*, 2013b). The K210E
159 substitution was maintained in this rescued virus in 100% of the reads at Psg 2 and Psg 3.

160 For the rescued serotype A viruses, consensus (Sanger) sequencing of the rescued O1K/A22 2A L2P
161 virus demonstrated the maintenance of the introduced changes and did not reveal any additional
162 modifications resulting in amino acid substitutions within the P1-2A coding region. This was
163 confirmed by NGS but an A to G nucleotide change, resulting in a single amino acid substitution
164 (T44 to A within the 2C protein), was found in 13% of the reads from the rescued virus (Table 2).
165 Within the O1K/A22 VP1 K210E and 2A L2P virus, only the expected changes in the P1-2A coding
166 region were observed but an additional change, resulting in the amino acid substitution A73V in the
167 2C protein, was detected in 100% of the sequence reads, see Table 2. The plasmid pO1K/A22 K210E
168 L2P from which this virus was rescued has been confirmed as having the expected sequence in the
169 2C coding region (100% identity to O1K, data not shown) and thus this sequence change had occurred

170 during virus rescue. The significance of these changes in 2C is unknown; neither residue is completely
171 conserved among FMDV strains (Carrillo *et al.*, 2005). The A73V change in 2C was not present in
172 the rescued O1K/A22 wt or the O1K/A22 2AL2P and there was no evidence for the T44A amino acid
173 substitution in either the O1K/A22 wt or the O1K/A22 VP1 K210E and 2A L2P virus that was
174 encoded in a minority of the O1K/A22 2A L2P virus reads.

175

176 *Exploring potential sequence diversity at the VP1/2A cleavage site.*

177 The results described previously (Gullberg *et al.*, 2013b; Gullberg *et al.*, 2014) indicated that
178 modification of the VP1/2A junction sequence from PxKQ/xLNF at the P2 position (from K to E) or
179 the P2' position (from L to P) was sufficient to strongly inhibit cleavage by 3C^{pro} at this protein
180 junction but these changes did not affect virus viability. Furthermore, the NGS data (Table 1)
181 indicated that the K to N substitution at residue 210 of VP1 was also probably viable since some 13%
182 of the virus population acquired this change. To establish the range of amino acid substitutions that
183 could be tolerated at this junction, mutagenesis of the codon for residue 210 within VP1 was
184 undertaken within the context of the O1K/A22 full-length cDNA. The mutagenesis generated 9
185 different codon sequences that encoded 7 distinct amino acid substitutions, see Table 3. RNA
186 transcripts were produced from the mutant cDNAs and electroporated into BHK cells and infectious
187 viruses were rescued in each case. From the virus harvests, RNA was extracted and the sequence of
188 VP1-2A coding region was determined, changes (if any) are shown in Table 3. Consistent with the
189 studies described above, the O1K/A22 VP1 K210E mutant (with a single nt change, GAA) again
190 reverted to the parental sequence, however when 2 nt changes were introduced (GAG) to produce the
191 K210E substitution then viruses that retained these 2 nt changes were obtained. Thus the VP1
192 substitutions K210Q, K210R, K210A, K210V, K210M, K210N and K210E (as the GAG double
193 mutant) were all viable without reversion or other adaptation within VP1 (Table 3). Using consensus

194 level sequencing, no changes in the 2C coding region were detected in any of these rescued viruses
195 either (data not shown).

196 The cleavage of the VP1/2A junction in cells infected with the rescued mutant viruses was assessed
197 using the IF assay, as described above. The presence of the FMDV capsid proteins (using anti-FMDV
198 antisera) and of the VP1-2A (using anti-2A antibodies) was determined in BHK cells infected with
199 the different viruses. FMDV infection, but with no staining for VP1-2A, was observed in cells
200 infected with the viruses containing the VP1 residue K210 (wt) and R210 (Fig. 4). In contrast, cells
201 infected with the rescued viruses having the substitutions in VP1 K210Q, K210A, K210V, K210M,
202 K210N and K210E (double mutant) each showed staining both for the FMDV capsid proteins and for
203 2A (using the anti-2A antisera), indicative of blocked VP1/2A cleavage (see Fig. 4 and Table 3). No
204 staining with either antiserum was observed in uninfected cells, as expected (Fig. 4).

205 To confirm these results, immunoblotting was performed using anti-2A antibodies to determine the
206 presence of the uncleaved VP1-2A within infected cells. The results are shown in Fig. 5(a). Consistent
207 with the IF results, no VP1-2A product was detected in uninfected cells or in wt (K210) or mutant
208 K210R FMDV-infected cells. In contrast, the presence of VP1-2A was readily apparent within cells
209 infected with mutant FMDVs having the K210Q, K210A, K210V, K210M, K210N and K210E
210 substitutions. The presence of FMDV capsid proteins in the lysates from cells infected with each of
211 the different FMDV variants was verified using anti-VP2 antibodies that recognizes both VP0 and
212 VP2 (Fig. 5(b)). These results support the IF data and indicate that the VP1/2A junction is only
213 cleaved when residue 210 in VP1 is either K or R (these are both basic residues).

214

215 **Discussion**

216 In our earlier studies, it was shown that the K210E substitution in VP1 within the FMDV O1M capsid
217 inhibited cleavage of the VP1/2A junction and resulted in generation of a second site substitution

218 (E83K in VP1) in the mutant virus (Gullberg *et al.*, 2013b). Furthermore, introduction of the E83K
219 substitution alone in VP1 resulted in the production of another second site change (with a substitution
220 of L2P in 2A) that also blocked VP1/2A junction processing in cells infected with the rescued virus
221 (Gullberg *et al.*, 2014). In contrast, this study, has shown that when the K210E substitution (GAA
222 mutant) was introduced into the VP1 of a serotype A virus (O1K/A22), the virus reverted to wt (AAA)
223 very rapidly (single nt change). However, introduction of 2 nt changes (GAG codon) enabled the
224 K210E substitution to be maintained. Consistent with the serotype O virus results (Gullberg *et al.*,
225 2013b; Gullberg *et al.*, 2014), this amino acid substitution alone was sufficient to block VP1/2A
226 cleavage (see Figs. 4 and 5). In addition, introduction of the 2A L2P change alone (employing 3 nt
227 changes) or also with the K210E substitution resulted in the generation of viruses which maintained
228 each of these changes. Furthermore, the presence of the uncleaved VP1-2A protein was observed
229 within cells infected with these serotype A viruses (Figs. 2 and 3). Thus, consistent with results using
230 the O1K/O1M FMDV (Gullberg *et al.*, 2013b; Gullberg *et al.*, 2014), it is possible to obtain infectious
231 serotype A FMDVs, containing the uncleaved VP1-2A. However, in contrast to the results using the
232 serotype O virus, there was no apparent selection for a substitution at residue E83 in VP1 (or
233 elsewhere within the VP1) within the serotype A background. The basis for this difference is not
234 known but it is noteworthy that the serotype A capsid proteins assemble into FMDV empty capsids
235 much more efficiently than the serotype O proteins (Abrams *et al.*, 1995; Porta *et al.*, 2013). It is also
236 apparent that some of the rescued serotype A viruses, with the VP1/2A junction rendered non-
237 cleavable, acquired second site mutations within the non-structural protein 2C (see Table 2). In
238 particular, the A73V variant within 2C was encoded by 100% of the sequence reads at Psg 3 of the
239 rescued O1K/A22 VP1-K210E and 2A-L2P virus. This suggests a strong selective pressure for this
240 amino acid substitution. The significance of this is currently unknown but there is some evidence for

241 interactions between the capsid proteins and the 2C protein of enteroviruses (e.g. poliovirus) during
242 virus morphogenesis (Liu *et al.*, 2010; Wang *et al.*, 2012; Wang *et al.*, 2014).

243 Interestingly, it was also observed, using NGS, that during the rescue of the O1K/O1M VP1 E83K
244 virus a minority of the virus population encoded a K210N substitution in VP1 (c.f. the K210E
245 substitution observed in a laboratory grown O1M virus, Gullberg *et al.*, 2013b). It should be noted
246 that the majority of the serotype O VP1 E83K mutant virus RNA acquired the 2A L2P substitution
247 during the virus rescue procedure (see Table 1). This encouraged analysis of the range of substitutions
248 that can be accommodated at residue 210 in VP1; this is at position P2 relative to the VP1/2A cleavage
249 site. Within the serotype A background, there appears to be significant selection pressure against the
250 K210E substitution, since following independent transfections of a mutant RNA containing a single
251 nt change (GAA) reversion to the wt (AAA) sequence occurred. However, when 2 nt changes were
252 used (GAG) to make this amino acid substitution then the K210E substitution was maintained. The
253 single nt substitution to make the K210E substitution was also maintained in the O1K/A22 K210E
254 and L2P double mutant; presumably the presence of the two substitutions that blocked VP1/2A
255 cleavage overcame the selective pressure for reversion. In addition, a range of other amino acid
256 substitutions were tolerated, most of these substitutions (e.g. K210A, K210V, K210M, K210N)
257 blocked cleavage of the VP1/2A junction, thus the VP1-2A product was stable (see Figs. 4 and 5). In
258 contrast, the 2A peptide was released from the VP1 in the K210R mutant. Therefore, it appears that
259 the presence of a positively charged residue (K or R) at residue 210 in VP1 is essential for VP1/2A
260 cleavage and a negative charge (as in K210E) is less well tolerated by itself and was selected against.
261 These results are consistent with the strong predominance of the K and R residues at this position in
262 the “logos plot” generated by Curry *et al.*, (2007) for 3C^{pro} cleavage sites, with Q at the P1 position,
263 based on the known sequences of over 100 strains of FMDV.

264 Using peptide cleavage assays, the VP1/2A peptide was the most efficiently cleaved substrate for
265 FMDV 3C^{pro} (Birtley *et al.*, 2005). However, making the K210A substitution abrogated cleavage of
266 this peptide, in accordance with the results presented here. Zunszain *et al.*, (2010), have described
267 additional modifications to the peptide substrate, which corresponds to the VP1/2A junction.
268 Changing the P2 residue in the cleavage site (corresponding to K210 in VP1) from K to R or to
269 ornithine (also positively charged) had relatively modest effects on the cleavage rate. However,
270 substitution to the neutral T residue abrogated cleavage as observed here with the K210 changed to
271 Q, A, V, M or N (see Table 3, Figs. 4 and 5).

272 It has been proposed that the FMDV 3C^{pro} may be a good target for the development of an antiviral
273 agent (Roqué Rosell *et al.*, 2014). Furthermore, it was shown that compounds that resemble the
274 peptide substrate can act as an efficient inhibitor of this protease. The presence of a positively charged
275 residue at the P2 position generated the most effective inhibitors while compounds containing neutral
276 residues (e.g. G and Q) or a negatively charged residue (E) at this position were much less effective,
277 consistent with the poor cleavage of the VP1/2A junction seen here in viruses containing equivalent
278 substitutions.

279 It is important to note that viable FMDVs with the VP1/2A junction uncleaved can be obtained (as
280 here, and as described previously for serotype O viruses, Gullberg *et al.*, 2013b; Gullberg *et al.*, 2014).
281 Thus, it may be wise to focus screens for such antiviral agents on other 3C^{pro} cleavage sites so that
282 the block on polyprotein processing is most effective at inhibiting virus replication.

283 The results presented here demonstrate that the combination of reverse genetics and NGS provides
284 powerful tools to direct and identify virus adaptation thus permitting novel aspects of the virus
285 biology to be identified.

286

287 **Material and Methods**

288 *Plasmid construction*

289 The structures of plasmids containing full-length FMDV cDNAs used in this study are indicated in
290 Fig.1. The chimeric pO1K/A22 plasmids (containing the A22 Iraq capsid coding sequences, as used
291 in Porta *et al.*, 2013; Polacek *et al.*, 2013) in the FMDV O1 Kaufbeuren (O1K) backbone were
292 generated using the same procedures as used previously for the production of the pO1K/O1M VP1
293 K210E (Gullberg *et al.*, 2013b). Briefly, the cDNAs corresponding to the A22 VP2-2A coding region
294 were amplified from pGEM-3Z-A-P1-2A-mIRES-3C (Gullberg *et al.*, 2013a) and pGEM-3Z-A-P1-
295 2A-mIRES-3C VP1K210E (Gullberg *et al.*, 2013b) with primers FMDVA_*Nhe*IVP4VP2_Fw and
296 FMDVA_*Apa*I2A2B_Re (see Supplementary Table S1) and used to generate the full-length cDNAs
297 termed pO1K/A22 wt and pO1K/A22 VP1 K210E, respectively (Fig.1). In order to produce
298 pO1K/A22 2A L2P and the double mutant pO1K/A22 VP1 K210E and 2A L2P, intermediate
299 plasmids (using pO1K/A22 wt and pO1K/A22 VP1K210E, as described above, as templates) were
300 generated. This was achieved using the QuikChange site-directed mutagenesis method (with
301 *Pfu*Turbo DNA polymerase; Stratagene), according to the manufacturer's instructions, with primers
302 containing the desired modifications (see Supplementary Table S1, namely FMDVA_2AL2P_Fw
303 together with FMDVA_2AL2P_Re or FMDVA_VP1K210E_2AL2P_Re). The subsequent steps to
304 produce the four pO1K/A22 variants were performed essentially as described for the serotype O
305 plasmid pO1K/O1M VP1 E83K (Gullberg *et al.*, 2014). Plasmids were amplified in *E. coli* Top10
306 cells (Invitrogen), purified (Midiprep kit; Thermo Scientific) and verified by sequencing of the capsid
307 coding region (and for pO1K/A22 VP1 K210E the 2C coding region as well) with a BigDye
308 Terminator v. 3.1 Cycle Sequencing Kit and a 3500 Genetic Analyzer (Applied Biosystems).
309 Additional mutations, encoding changes at the VP1/2A junction, were introduced into the pO1K/A22
310 full-length FMDV cDNA (Fig.1) by site-directed mutagenesis using a megaprimer (146 bp) that was
311 prepared by PCR using primer O1PN20 and primer 13LPN21, (see Supplementary Table S1), that

312 had NNN at the position corresponding to the codon for the VP1 residue 210. This degenerate
313 megaprimer was used, with the pO1K/A22 full-length cDNA template and *Pfu*Turbo DNA
314 polymerase (as above) to generate a collection of 9 plasmids encoding a variety of different amino
315 acids, with diverse properties, in place of VP1 residue K210; this is at position P2 relative to the
316 VP1/2A cleavage site. The details of each modification made are indicated in Table 3.

317

318 *Rescue of modified viruses from cDNA.*

319 Plasmids pO1K/A22 (wt), pO1K/A22 VP1 210E, pO1K/A22 2A L2P and pO1K/A22 VP1 K210E
320 2A L2P, (as shown in Fig.1) containing the full-length FMDV cDNA sequences were linearized by
321 digestion with *Hpa*I, purified (using a QIAquick PCR purification kit; Qiagen) and transcribed *in*
322 *vitro* using T7 RNA polymerase (Megascript kit; Ambion). The transcripts were analyzed using
323 agarose gel electrophoresis and then introduced into baby hamster kidney (BHK) cells by
324 electroporation as described previously (Nayak *et al.*, 2006; Bøtner *et al.*, 2011). At 2 days post
325 electroporation, the rescued viruses were harvested and amplified in one, or two, subsequent passages
326 (Psg 2 and Psg3) in BHK cells. After these passages, viral RNA was extracted (QIAamp RNA blood
327 mini kit; Qiagen), reverse transcribed using ready-to-go you-prime first-strand beads (GE Healthcare
328 Life Sciences), and the FMDV cDNA corresponding to the VP2-2A coding region was amplified in
329 a PCR (Expand high-fidelity PCR system; Roche). Control reactions, lacking reverse transcriptase,
330 were used to show that the PCR products obtained were derived from the viral RNA and not from
331 residual DNA template. The amplicons (~2,000 bp) including the entire VP2-2A coding region were
332 visualized in agarose gels, purified (GeneJET gel extraction kit, Thermo Scientific) and sequenced,
333 on both strands, as above. Sequences were analysed using Vector NTI software (Invitrogen).

334 For the library of VP1 K210 mutants, mutant viruses were rescued essentially as described above.

335 The sequencing covered the VP1-2A coding region (from a PCR product of ca. 700bp) both before

336 and after virus rescue. The sequence of the 2C coding region was also determined in selected cases.
337 The rescued viruses were titrated (and were in most cases ca. 10^6 to 10^7 TCID₅₀/ml), in some cases a
338 4th passage in BHK cells was required to reach this titre.

339 The rescued serotype O viruses O1K/O1M VP1 E83K and O1K/O1M VP1 K210E viruses have been
340 described previously (Gullberg *et al.*, 2013b; Gullberg *et al.*, 2014).

341

342 *RT-PCR and Next Generation Sequencing (NGS).*

343 For the purpose of NGS, extracted RNA (isolated as described above from virus harvests) was
344 converted to cDNA using SuperScript III (Invitrogen) with a T₂₇ reverse primer according to the
345 manufacturer's protocol. Two cDNA amplicons were prepared by PCR using Phusion DNA
346 polymerase (Thermo Fisher) with the primers 13-N PN 2 + 10-P PN 30 (Supplementary Table S1)
347 and separately 8-A PN 200 + 13-N PN 3 (Supplementary Table S1). These overlapping fragments
348 (ca. 4kb and 4.2kb respectively) correspond to the most of the FMDV genome (downstream of the
349 poly(C) tract, see Belsham (2005)), including the complete polyprotein coding region (ca. 7kb) but
350 excluding the S-fragment at the 5'-terminus of the viral genome. The fragments were gel purified,
351 mixed and then analysed by NGS essentially as described previously (Fahnøe *et al.*, 2014; Hadsbjerg
352 *et al.*, 2016). The parental sequences of the FMDV chimeric O1K/O1M cDNA (as described by
353 Gullberg *et al.*, 2013b) was assembled from the O1K sequence (Acc. No. X00871) and the coding
354 sequence for the O1M capsid proteins (from Acc. No. AY593823) with known differences (see
355 Gullberg *et al.*, 2013b), while the chimeric O1K/A22 sequence was generated using the O1K
356 sequence and the A22 Iraq sequence (Carrillo *et al.*, 2005, Acc. No. AY593764.1). The derived
357 sequences were used as the reference for mapping of sequence reads using Samtools (Li *et al.*, 2009),
358 VarScan 2 (Koboldt *et al.*, 2012) and VCFtools (Danecek *et al.*, 2011), in succession, in order to
359 generate consensus sequences from the mapped reads. Subsequently, consensus sequences were

360 aligned using MAFFT in Geneious (Biomatters, Auckland, New Zealand). Finally, a combination of
361 Samtools (Li *et al.*, 2009), Lo-Freq (Wilm *et al.*, 2012) and SnpEff (Cingolani *et al.*, 2012) was used
362 for downstream single nucleotide variant (SNV) analysis.

363

364 *Virus infection of BHK cells.*

365 Virus titers were determined, as tissue culture infectious doses (TCID₅₀), by titration in BHK cells
366 according to standard procedures (Reed & Muench, 1938).

367 Monolayers of BHK cells, grown in 35-mm wells, were inoculated with the rescued viruses at a
368 multiplicity of infection (MOI) of 0.1 TCID₅₀/cell. At the indicated times post infection, cell lysates
369 were prepared using 20 mM Tris-HCl (pH 8.0), 125 mM NaCl and 0.5% NP-40, and clarified by
370 centrifugation at 18,000 × g for 10 min at 4°C.

371

372 *Immunoblot analysis.*

373 Immunoblotting was performed, using cell lysates, according to standard methods as described
374 previously (Polacek *et al.*, 2013). Briefly, aliquots of cell lysate were mixed with Laemmli sample
375 buffer (with 25mM dithiothreitol), the proteins were separated by SDS-PAGE (12.5% or 4-15%
376 polyacrylamide) and transferred to polyvinylidene difluoride membranes (PVDF, Millipore). Specific
377 proteins were detected with primary antibodies recognizing: FMDV VP2 (monoclonal antibody 4B2,
378 a gift from L. Yu, as described by Yu *et al.*, 2011) and FMDV 2A (ABS31; Millipore). Bound proteins
379 were visualized using appropriate horseradish peroxidase-conjugated secondary antibodies (Dako)
380 and a chemiluminescence detection kit (ECL Prime, Amersham) with a Chemi-Doc XRS system
381 (Bio-Rad).

382

383 *Immunofluorescence assays.*

384 Monolayers of BHK cells, grown on glass coverslips in 35-mm well plates, were infected with the
385 rescued O1K/A22 viruses (MOI 0.1). At 6-8 hrs post infection, the cells were fixed, stained and
386 mounted as previously described (Gullberg *et al.*, 2013b) using rabbit anti-FMDV A-Iraq serum and
387 anti-FMDV 2A (ABS31, as above) followed by a donkey Alexa-fluor 568-labelled anti-rabbit IgG
388 (A10042, Life Technologies). The slides were mounted with Vectashield (VECTOR laboratories)
389 containing 4',6-diamidino-2-phenylindole (DAPI) and images were captured using an
390 epifluorescence microscope.

391

392 **Acknowledgements**

393 We wish to thank Li Yu (Chinese Academy of Agricultural Sciences, China) for the anti-VP2
394 antibody. This work was supported by the Danish Council for Independent Research-Technology and
395 Production Sciences (FTP grant 09-070549) to CP and GJB.

396

397 **References**

398 **Abrams, C.C., King, A.M. & Belsham, G.J. (1995).** Assembly of foot-and-mouth disease virus
399 empty capsids synthesized by a vaccinia virus expression system. *J Gen Virol* **76**, 3089-3098.

400

401 **Atkins, J.F., Wills, N.M. Loughran, G., Wu, C.Y., Parsawar, K., Ryan, M.D., Wang, C.H. &**
402 **Nelson, C.C. (2007).** A case for “StopGo”: reprogramming translation to augment codon meaning of
403 GGN by promoting unconventional termination (Stop) after addition of glycine and then allowing
404 continued translation (Go). *RNA* **13**, 803-810.

405

406 **Belsham, G.J. (2005).** Translation and replication of FMDV RNA. *Curr Top Microbiol Immunol*
407 **288**, 43-70.

408

409 **Birtley, J.R., Knox, S.R., Jaulent, A.M., Brick, P., Leatherbarrow, R.J. & Curry S. (2005).**
410 Crystal structure of foot-and-mouth disease virus 3C protease. New insights into catalytic mechanism
411 and cleavage specificity. *J Biol Chem* **280**, 11520-11527.

412

413 **Bøtner, A., Kakker, N.K., Barbezange, C., Berryman, S., Jackson, T. & Belsham, G.J. (2011).**
414 Capsid proteins from field strains of foot-and-mouth disease virus confer a pathogenic phenotype in
415 cattle on an attenuated, cell-culture-adapted virus, O1 Kaufbeuren virus. *J Gen Virol* **92**, 1141-1151.

416

417 **Carrillo, C., Tulman, E.R., Delhon, G., Lu, Z., Carreno, A., Vagnozzi, A., Kutish, G.F. & Rock,**
418 **D.L. (2005).** Comparative genomics of foot-and-mouth disease virus. *J Virol* **79**, 6487-6504.

419

420 **Cingolani, P., Platts, A., Wang, L.L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X. &**
421 **Ruden, D.M. (2012).** A program for annotating and predicting the effects of single nucleotide

422 polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3.
423 *Fly (Austin)*. **6**, 80-92.

424

425 **Curry, S., Abrams, C.C., Fry, E., Crowther, J.C., Belsham, G.J., Stuart, D.I. & King, A.M.**
426 **(1995)**. Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids. *J Virol* **69**,
427 430-438.

428

429 **Curry, S., Roque-Rosell, N., Zunszain, P.A. & Leatherbarrow, R.J. (2007)**. Foot-and-mouth
430 disease virus 3C protease: recent structural and functional insights into an antiviral target. *Int J*
431 *Biochem Cell Biol* **39**, 1-6.

432

433 **Danecek, P., Auton, A., Abecasis, G., Albers, C.A., Banks, E., DePristo, M.A., Handsaker, R.E.,**
434 **Lunter, G., Marth, G.T., Sherry, S.T., McVean, G. & Durbin, R. (2011)**. The variant call format
435 and VCFtools. *Bioinformatics*. **27**, 2156–2158.

436

437 **Donnelly, M.L., Luke, G., Mehrotra, A., Li, X., Hughes, L.E., Gani, D. & Ryan MD. (2001)**.
438 Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic
439 reaction, but a novel translational effect: a putative ribosomal 'skip'. *J Gen Virol* **82**, 1013-1025.

440

441 **Ellard, F.M., Drew, J., Blakemore, W.E., Stuart, D.I. & King, A.M. (1999)**. Evidence for the role
442 of His-142 of protein 1C in the acid-induced disassembly of foot-and-mouth disease virus capsids. *J*
443 *Gen Virol* **80**, 1911-1918.

444

445 **Fahnøe, U., Pedersen, A.G., Risager, P.C., Nielsen, J., Belsham, G.J., Höper, D., Beer, M. &**
446 **Rasmussen, T.B. (2014).** Rescue of the highly virulent classical swine fever virus strain "Koslov"
447 from cloned cDNA and first insights into genome variations relevant for virulence. *Virology* **468-470**,
448 379-387.

449

450 **Gullberg, M., Muszynski, B., Organtini, L.J., Ashley, R.E., Hafenstein, S.L., Belsham, G.J. &**
451 **Polacek C. (2013a).** Assembly and characterization of foot-and-mouth disease virus empty capsid
452 particles expressed within mammalian cells. *J Gen Virol* **94**, 1769-1779.

453

454 **Gullberg, M., Polacek, C., Bøtner, A. & Belsham, G.J. (2013b).** Processing of the VP1/2A junction
455 is not necessary for production of foot-and-mouth disease virus empty capsids and infectious viruses:
456 characterization of "self-tagged" particles. *J Virol* **87**, 11591-11603.

457

458 **Gullberg, M., Polacek, C. & Belsham, G.J. (2014).** Sequence adaptations affecting cleavage of the
459 VP1/2A junction by the 3C protease in foot-and-mouth disease virus-infected cells.
460 *J Gen Virol* **95**, 2402-2410.

461

462 **Hadsbjerg, J., Friis, M.B., Fahnøe, U., Nielsen, J., Belsham, G.J. & Rasmussen, T.B. (2016).**
463 Sequence adaptations during growth of rescued classical swine fever viruses in cell culture and within
464 infected pigs. *Vet Micro* **192**, 123-134.

465

466 **Koboldt, D., Zhang, Q., Larson, D., Shen, D., McLellan, M., Lin, L., Miller, C., Mardis, E.,**
467 **Ding, L. & Wilson, R. (2012).** VarScan 2: Somatic mutation and copy number alteration discovery
468 in cancer by exome sequencing. *Genome Research* **22**, 568-576. URL:<http://varscan.sourceforge.net>

469

470 **Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G.,**
471 **Durbin, R. & 1000 Genome Project Data Processing Subgroup. (2009).** The Sequence
472 Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079.

473

474 **Liu, Y., Wang, C., Mueller, S., Paul, A.V., Wimmer, E. & Jiang, P. (2010)** Direct interaction
475 between two viral proteins, the nonstructural protein 2C and the capsid protein VP3, is required for
476 enterovirus morphogenesis. *PLoS Pathog.* **6(8)**, e1001066.

477

478 **Medina, M., Domingo, E., Brangwyn, J.K. & Belsham, G.J. (1993).** The two species of the foot-
479 and-mouth disease virus leader protein, expressed individually, exhibit the same activities. *Virology*
480 **194**, 355-359.

481

482 **Nayak, A., Goodfellow, I.G., Woolaway, K.E., Birtley, J., Curry, S. & Belsham, G.J. (2006).**
483 Role of RNA structure and RNA binding activity of foot-and-mouth disease virus 3C protein in VPg
484 uridylation and virus replication. *J Virol* **80**, 9865-9875.

485

486 **Polacek, C., Gullberg, M., Li, J. & Belsham, G.J. (2013).** Low levels of foot-and-mouth disease
487 virus 3C protease expression are required to achieve optimal capsid protein expression and processing
488 in mammalian cells. *J Gen Virol* **94**, 1249-1258.

489

490 **Porta, C., Xu, X., Loureiro, S., Paramasivam, S., Ren, J., Al-Khalil, T., Burman, A., Jackson,**
491 **T., Belsham, G.J., Curry, S., Lomonosoff, G.P., Parida, S., Paton, D., Li, Y., Wilsden, G.,**
492 **Ferris, N., Owens, R., Kotecha, A., Fry, E., Stuart, D.I., Charleston, B. & Jones, I.M. (2013).**

493 Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down
494 regulation of 3C protease activity. *J Virol Methods*. **187**, 406-412.

495

496 **Reed, L.J. & Muench, H. (1938)**. A simple method of estimating fifty percent endpoints. *Am J Hyg*
497 **27**, 493-497.

498

499 **Roqué Rosell, N.R., Mokhlesi, L., Milton, N.E., Sweeney, T.R., Zunszain, P.A., Curry, S. &**
500 **Leatherbarrow, R.J. (2014)**. Design and synthesis of irreversible inhibitors of foot-and-mouth
501 disease virus 3C protease. *Bioorg Med Chem Lett*. **24**, 490-494.

502

503 **Ryan, M.D., Belsham, G.J. & King, A.M. (1989)**. Specificity of enzyme-substrate interactions in
504 foot-and-mouth disease virus polyprotein processing. *Virology* **173**, 35-45.

505

506 **Strebel, K. & Beck E. (1986)**. A second protease of foot-and-mouth disease virus. *J Virol* **58**, 893-
507 899.

508

509 **Wang, C., Jiang, P., Sand, C., Paul, A.V. & Wimmer, E. (2012)** Alanine scanning of poliovirus
510 2CATPase reveals new genetic evidence that capsid protein/2CATPase interactions are essential for
511 morphogenesis. *J Virol*. **86**, 9964-9975.

512

513 **Wang C, Ma HC, Wimmer E, Jiang P & Paul AV. (2014)** A C-terminal, cysteine-rich site in
514 poliovirus 2C(ATPase) is required for morphogenesis. *J Gen Virol*. **95**, 1255-1265.

515

516 **Wilm, A., Aw, P.P., Bertrand, D., Yeo, G.H., Ong, S.H., Wong, C.H., Khor, C.C., Petric, R.,**
517 **Hibberd, M.L. & Nagarajan, N. (2012).** LoFreq: a sequence-quality aware, ultra-sensitive variant
518 caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. *Nucl.*
519 *Acids Res.* **40**, 11189-11201.

520

521 **Yu, Y., Wang, H., Zhao, L., Zhang, C., Jiang, Z. & Yu, L. (2011).** Fine mapping of a foot-and-
522 mouth disease virus epitope recognized by serotype-independent monoclonal antibody 4B2. *J*
523 *Microbiol* **49**, 94-101.

524

525 **Zunszain, P.A., Knox, S.R., Sweeney, T.R., Yang, J., Roque-Rosell, N., Belsham, G.J.,**
526 **Leatherbarrow, R.J. & Curry, S. (2010).** Insights into cleavage specificity from the crystal structure
527 of foot-and-mouth disease virus 3C protease complexed with a peptide substrate. *J Mol Biol* **395**,
528 375-389.

529

530 TABLES

531 Table 1. Analysis of SNVs within rescued O1K/O1M viruses as determined by NGS.

Nt position	wt	Variant	O1K/O1M	O1K/O1M	O1K/O1M	SNV effect (whole polyprotein)	SNV effect (individual protein)
			VP1 E83K (Psg 2) (%) ¹	VP1 K210E (Psg 2) (%) ¹	VP1 K210E (Psg 3) (%) ¹		
762	T	C	6	-	-	(in 5' UTR)	-
948	T	G	-	1	3	(in 5' UTR)	-
1811	T	C	6	-	-	-	-
1875	A	G	3	-	-	T253A	VP4 (T52A)
2102	C	T	3	-	-	-	-
2357	A	G	-	3	3	-	-
3537	G	A	100	78	99	E807K	VP1 (E83K)
3918	A	G	-	100	100	K934E	VP1 (K210E)
3920	A	C	4	-	-	K934N	VP1 (K210N)
3920	A	T	9	-	-	K934N	VP1 (K210N)
3928	T	C	83	-	-	L937P	2A (L2P)
5166	A	G	3	-	-	S1350G	2C (S243G)
7392	T	C	-	5	7	F2092L	3D (F228L)
7765	A	G	2	-	-	K2216R	3D (K353R)

532

533 1: The percentage of each variant ($\geq 1\%$) is given to the nearest integer.

534

535 **Table 2. Analysis of SNVs within rescued O1K/A22 viruses as determined by NGS.**

Nt position	wt	Variant	O1K/A22	O1K/A22	O1K/A22 VP1	SNV effect (whole polyprotein)	SNV effect (individual protein)
			(wt)	2A L2P	K210E 2A L2P		
			(Psg 2)	(Psg 3)	(Psg 3)		
			(%) ¹	(%) ¹	(%) ¹		
932	A	C	-	2	-	(in 5'-UTR)	-
1060	T	G	2	-	-	(in 5'-UTR)	-
1124	T	A	-	7	-	N2K	L (N2K)
1341	C	T	-	-	4	P75S	L (P75S)
1400	G	T	-	-	2	-	-
1865	C	T	-	2	-	-	-
2175	T	C	-	2	-	F353L	VP2 (F67L)
2342	A	G	-	-	2	-	-
2684	C	T	-	3	-	-	-
3154	T	C	-	1	-	V679A	VP3 (V174A)
3824	G	C	2	-	-	-	-
3884	T	C	-	8	-	-	-
3921	A	G	-	-	100	K935E	VP1 (K210E)
3930	T	C	-	90	100		
3931	T	C	-	98	100	L938P ²	2A (L2P) ²
3932	G	A	-	99	100		
4572	A	G	-	13	-	T1152A	2C (T44A)
4660	C	T	-	-	100	A1181V	2C (A73V)
4821	A	C	-	1	-	I1235L	2C (I127L)
4843	G	T	-	1	-	R1242I	2C (R134I)
5080	C	T	-	5	-	T1321I	2C (T213I)
6924	C	T	-	11	-	-	-
7170	T	C	3	-	-	Y2018H	3D (Y155H)
7358	C	T	-	-	4	-	-

536
537 1: The percentage of each variant ($\geq 1\%$) is given to the nearest integer.

538 2: Change of the TTG to CCA codon was introduced by site-directed mutagenesis and the 3
539 changes together result in the 2A (L2P) substitution.

540

541

542 **Table 3. Influence of residue K210 in VP1 on VP1/2A junction cleavage in FMDV-infected**
 543 **cells.**

Virus	VP1 210 codon	Viability	Rescued virus sequence	Rescued virus amino acid	Comment	VP1/2A cleavage ¹
pO1K/A22 K210	AAA	+	AAA	K	wt	+
pO1K/A22 K210Q	CAA ²	+	CAA	Q		-
pO1K/A22 K210R	AGA ²	+	AGA	R		+
pO1K/A22 K210A(v1) ³	GCA ²	+	GCA	A		-
pO1K/A22 K210A(v2) ³	GCG ²	+	GCG	A		-
pO1K/A22 K210V	GTT ²	+	GTT	V		-
pO1K/A22 K210M	ATG ²	+	ATG	M		-
pO1K/A22 K210N	AAC ²	+	AAC	N		-
pO1K/A22 K210E(v1) ³	GAA ²	+	AAA	K	Reversion	+
pO1K/A22 K210E(v2) ³	GAG ²	+	GAG	E		-

544

545 1: VP1/2A cleavage was assessed from IF staining using anti-2A antibodies (as in Fig. 4) and by
 546 immunoblotting (Fig. 5(a)).

547 2: nt changes in this codon are indicated in bold font.

548 3: (v1 or v2 to distinguish different codons)

549

550 **Figure legends**

551

552 **Figure 1. Schematic structure of the plasmid containing the FMDV O1K/A22 cDNA and**

553 **derivatives.** The *NheI* and *ApaI* restriction enzyme sites (as indicated) were used as described in

554 Materials and Methods to introduce cDNA fragments encoding the serotype A FMDV capsid proteins

555 VP2-VP3-VP1-2A (from A22 Iraq, white fill) into the plasmid pT7S3 (Ellard *et al.*, 1999), containing

556 a full-length cDNA corresponding to the O1Kaufbeuren B64 strain of FMDV (coding sequences

557 marked in grey). The plasmid encoded amino acid sequences at the VP1/2A junction are shown. The

558 FMDV O1K/A22 wild-type, single mutants (VP1 K210E or 2A L2P) and double mutant (VP1 K210E

559 and 2A L2P) were produced as described in Materials and Methods. The full-length plasmids were

560 linearized using *HpaI* prior to *in vitro* transcription and virus rescue. The locations of restriction sites

561 used are marked: *NheI*, *ApaI* and *HpaI*. Sequence changes in the capsid coding region of the rescued

562 viruses are indicated.

563

564 **Figure 2. Detection of FMDV capsid proteins in BHK cells infected with O1K/A22 wild-type**

565 **and mutant viruses.** BHK cells were infected with O1K/A22 wild-type or mutant viruses (single

566 mutant 2A L2P or double mutant VP1 K210E and 2A L2P) (MOI of 0.1) and whole cell lysates were

567 prepared at the indicated times post infection. The presence of FMDV VP2 (and its precursor VP0)

568 were detected by immunoblotting using anti-VP2 antibodies (panel (a)) and FMDV 2A (attached to

569 VP1 as VP1-2A) was detected using anti-2A antibodies (panel (b)). Uninfected BHK cells were used

570 as a negative control. Molecular mass markers (kDa) are indicated on the left.

571

572 **Figure 3. Immunofluorescence staining of FMDV proteins within serotype A FMD virus-**

573 **infected cells.** FMDV proteins within uninfected or FMDV-infected cells (using MOI of 0.1) were


574 detected (at 8 h p.i.) using an anti-FMDV A-Iraq polyclonal antibody (panels (a) - (d)) or an anti-2A


575 antibody (panels (e) - (h)) and a secondary antibody labeled with Alexa Fluor 568 (red). Uninfected
576 cells are shown in panels (a) and (e). Cells were infected with the viruses O1K/A22 (wild-type)
577 (panels (b) and (f)), O1K/A22 2A L2P (panels (c) and (g)) or O1K/A22 VP1 K210E and 2A L2P
578 (panels (d) and (h)) as indicated. The cellular nuclei were visualized with DAPI (blue). Bar, 50 μ m.
579

580 **Figure 4. Determination of VP1/2A cleavage by immunofluorescence staining for FMDV**
581 **proteins within cells.** FMDV proteins within uninfected or FMDV-infected cells (using MOI of
582 0.1) were detected (at 6 h p.i.) using an anti-FMDV A-Iraq polyclonal antibody or an anti-2A
583 antibody (as indicated) and a secondary antibody labeled with Alexa Fluor 568 (red) as in Fig. 3.
584 The codon for residue 210 within VP1 (in parentheses) and the resulting individual amino acid
585 residue within the different rescued viruses are indicated. Uninfected cells were used as a negative
586 control. The cellular nuclei were visualized with DAPI (blue). Bar, 200 μ m.

587
588 **Figure 5. Assessment of FMDV VP1/2A cleavage in FMDV-infected BHK cells by**
589 **immunoblotting.** Uninfected or FMDV-infected BHK cell lysates were analysed by SDS-PAGE
590 and immunoblotting (as in Fig. 2). Where applicable, the cells were infected with the indicated
591 viruses (at an MOI of 0.1) and the presence of FMDV 2A (attached to VP1 as VP1-2A) was
592 detected using anti-2A antibodies (panel (a)) while FMDV VP2 (and its precursor VP0) were
593 detected by immunoblotting using anti-VP2 antibodies (panel (b)). Uninfected cells were used as a
594 negative control. Molecular mass markers (kDa) are indicated on the left.

595








Fig. 3




Figure 4




Fig. 5

Supplementary Table S1. Primers used for plasmid construction and cDNA synthesis

Primer name	Sequence (5'-3')
FMDVA_ <i>Nhe</i> IVP4VP2_Fw	CGCTCT <u>GCTAGCC</u> GATAAGAAGACCGAGGAGACCA
FMDVA_ <i>Apa</i> I2A2B_Re	CTACTAG <u>GGCCC</u> GGGGTTGGACTCAACGTCTCCTG
FMDVA_2AL2P_Fw	CAACTT <i>CCAA</i> ACTTCGATTTGCTCAAGTTGGCAGGAGAC
FMDVA_2AL2P_Re	GAAGTT <i>TGG</i> AAGTTGTTTTGCAGGTGCAATGATCTTCTG
FMDVA_VP1K210E_2AL2P_Re	GAAGTT <i>TGG</i> AAGTTGTTCTGCAGGTGCAATGATCTTCTG
13-N PN2	AAGTTTTACCGTCGTTCCCGACGTAAAAGGGAGGTAACCAC AAGCTTGAA
10-P PN 30	TCTGGACAGCACCTTTGTCG
8-A PN 200	GAGACGTTGAGTCCAACCC
13-N PN 3	CCGTAGGAGTGAAAATCCCGAAAGGGTTTTTCCCGCTTCCTT AATCCAAA
O1PN20	GACATGTCCTCCTGCATCTG
13LPN21	GCACCTGCAN <i>NN</i> CAACTTTTGAAC

^a Underlined sequences represent restriction enzyme sites *NheI* and *ApaI*. Nucleotide changes producing amino acids substitutions are shown in boldface italics.